Steven Moss

Chief Technology Officer @Isomerase

Cambridge, GB
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Jan 2013 — Present

Chief Technology Officer @Isomerase

View department →

Isomerase Therapeutics is a drug discovery and development company based in Cambridge, UK, with particular expertise in the discovery and development of optimised microbial natural products. We offer a proven route to develop these hits into drugs via our unique biosynthetic medicinal chemistry services. We offer this bespoke biosynthetic engineering/semi-synthetic chemistry platform and drug discovery and development expertise on a FTE basis to partners looking for more than just a CRO. Isomerase Therapeutics can help you take your chosen natural product from an interesting hit to a high value candidate drug.

EDUCATION

1996 — 1999

Durham University

PhD, Chemistry

1993 — 1996

Durham University

BSc, Chemistry

1999 — 2001

University of Washington

Postdoctoral studies, Chemistry

SKILLS

Drug DiscoveryMedicinal ChemistryBiotechnologyTechnology TransferHplcDrug DevelopmentChemistryPharmaceutical IndustryPurificationR&DOrganic SynthesisOrganic ChemistryLifesciences

ABOUT STEVEN MOSS

Highly practiced at applying the chemical biology of microbial natural products to drug discovery. In particular, experienced in applying Isomerase\'s bioengineering platform and semi-synthesis to generate microbial natural products with characteristics more suited to use as pharmaceuticals than the parent. From 2009 until 2013, I was the Director of Natural Products Chemistry at Biotica Technology Ltd, with responsiblity for all internal fermentation and chemistry as well as the management and technology transfer associated with outsourced manufacture and chemistry. I joined Biotica in 2002 as a Research Scientist and worked on a number of different microbial natural product based programmes across multiple therapeutic areas. Prior to that, I spent two years as a Post-Doctoral Research Associate with Professor Heinz G. Floss (University of Washington, Seattle) studying the biosynthesis of ansamitocin. Steven holds a BSc and PhD in Chemistry from the University of Durham, where he studied under Professor David O\'Hagan. He is an author or inventor on over 40 scientific papers and US/EU patents.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Steven Moss — Chief Technology Officer at Isomerase in Cambridge, GB | Unifers